CSF and serum PRXs levels in patients
CSF PRX1 levels were 2.10 ± 2.72 (mean ± SD), 1.27 ± 1.54, and
1.84 ± 1.68 ng/ml; CSF PRX5 levels were 1.17 ± 0.28, 2.20 ± 4.74, and
1.26 ± 0.41 ng/ml; and CSF PRX6 levels were 3.94 ± 5.49, 2.15 ± 1.91,
and 2.42 ± 3.70 ng/ml in patients with NMOSD, MS, and ONDs,
respectively. There were no significant differences in the levels of
PRXs in the CSF among the groups of patients (Figure 1).
Serum PRX1 levels were 13.88 ± 20.74, 7.24 ± 10.50, and
2.28 ± 3.98 ng/ml; serum PRX5 levels were 5.47 ± 6.54, 1.77 ± 1.28, and
0.98 ± 0.00 ng/ml; and serum PRX6 levels were 43.81 ± 41.21,
22.72 ± 11.47, and 6.25 ± 4.75 ng/ml in patients with NMOSD, MS, and
ONDs, respectively. Serum PRX5 and PRX6 levels in patients with NMOSD
and MS were significantly higher than those in patients with ONDs (PRX5:
NMOSD vs. ONDs, P = 0.013; MS vs. ONDs, P = 0.031, PRX6: NMOSD vs. ONDs,
P = 0.0003; MS vs. ONDs, P = 0.0009) (Figure 1).